Modality
Gene Therapy
MOA
Cl18.2
Target
VEGF
Pathway
PD-1/PD-L1
CSUGBM
Development Pipeline
Preclinical
Jun 2017
→ Sep 2029
PreclinicalCurrent
NCT07018356
666 pts·CSU
2019-05→2029-08·Completed
NCT07645707
734 pts·CSU
2017-06→2029-09·Completed
1,400 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-08-133.4y awayInterim· CSU
2029-09-223.5y awayInterim· CSU
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2029-08-13 · 3.4y away
CSU
Interim
2029-09-22 · 3.5y away
CSU
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07018356 | Preclinical | CSU | Completed | 666 | EASI-75 |
| NCT07645707 | Preclinical | CSU | Completed | 734 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |